Prolactin Levels in Premenopausal Women Treated With Risperidone Compared With Those of Women Treated With Typical Neuroleptics

Caracci, Giovanni; Ananthamoorthy, Renuka

doi:10.1097/00004714-199904000-00025

Cited by 20 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding supports the results of previous reports based on group comparisons (Shiwach and Carmody 1998;Caracci and Ananthamoorthy 1999;David et al 2000). Previous clinical trials have suggested the equivalent efficacy when recommended doses were given, e.g., risperidone 4-8 mg/day versus haloperidol 10 mg/day (Curtis and Kerwin 1995).…”

Section: Discussionsupporting

confidence: 91%

“…However, side effects associated with hyperprolactinemia (Dickson et al 1995;Popli et al 1998;Kim et al 1999) have been reported. Except for a retrospective analysis (Kleinberg et al 1999), it has been demonstrated that the pronounced hyperprolactinemia (Shiwach and Carmody 1998;Caracci and Ananthamoorthy 1999;Lavalaye et al 1999;David et al 2000) is consistently induced by risperidone treatment rather than conventional antipsychotic agents, although these studies were conducted using group comparisons or scattering doses of neuroleptics. Moreover, the effects of neuroleptic concentrations were not taken into account in these studies despite the fact that plasma drug concentration is one important factor to affect plasma prolactin concentration (Yasui et al 1998;Yasui-Furukori et al 2001).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia

et al. 2002

View full text Add to dashboard Cite

The present study aimed to investigate intraindividual changes in plasma prolactin concentrations by switching from haloperidol treatment to risperidone treatment. The subjects were 15 female schizophrenic inpatients who received firstly haloperidol 12 mg/day for at least 2 weeks and, thereafter, risperidone 6 mg/day. Prolactin concentration in plasma during risperidone treatment (median 87.5 ng/ml, range 5.3-298.1 ng/ml) was significantly ( P<0.01) higher than during haloperidol treatment (median 50.7 ng/ml, range 11.6-226.6 ng/ml). In contrast, the ratio of prolactin concentration to nmol/l unit drug concentration (the active moiety: the sum of risperidone and 9-hydroxyrisperidone) during risperidone treatment (median 1.10, range 0.02-3.73) was significantly lower ( P<0.001) than that of haloperidol (median 1.81, range 0.41-8.24). Prolactin concentrations during both treatment phases correlated well in individuals (r=0.619, P<0.05), whereas better correlation was found in the ratio of prolactin concentration to drug concentration (r=0.779, P<0.01). These findings suggest the higher risk of hyperprolactinemia during risperidone treatment than during haloperidol treatment at clinically used dosages. However, from a purely pharmacological point of view, prolactin response per drug concentration was more sensitive during haloperidol treatment than risperidone treatment, probably resulting from the potent and selective antagonistic effect of haloperidol on dopamine D(2) receptor, compared with the broader pharmacological spectrum of risperidone.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Caracci randomly selected two groups of 20 patients from premenopausal women admitted to an in-patient unit in order to compare prolactin levels between women receiving risperidone and those receiving conventional antipsychotics [55]. The mean prolactin levels were significantly higher (102 vs. 48 mcg/l, p = 0.00001) in the risperidone group.…”

Section: Prolactinmentioning

confidence: 99%

Pharmacology and clinical experience with risperidone

Love¹,

Nelson²

2000

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Risperidone (Risperdal, Janssen Pharmaceutica) is a second generation antipsychotic (SGA) for the treatment of schizophrenia and other psychotic disorders. It is a potent antagonist of serotonin-2 (5-HT2) and dopamine-2 (D2) receptors in the brain. In comparison to conventional antipsychotics, risperidone demonstrates superior efficacy against the positive and negative symptoms of schizophrenia and a decreased occurrence of extrapyramidal side effects (EPS). Risperidone causes less weight gain than other marketed SGAs, but can increase prolactin levels and cause EPS in a dose-related manner. In a variety of pharmacoeconomic analyses, it has proven to be a cost-effective addition to the antipsychotic armamentarium. As the first SGA available for front line use, risperidone has established a new standard of care for the treatment of individuals with psychotic disorders.

show abstract